PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES **DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER 033393-055222

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) PRIORITY DATE CLAIMED

INTERNATIONAL APPLICATION NO. PCT/US2004/036200 INTERNATIONAL FILING DATE

01 November 2004 (1.11.2004)

30 October 2003 (30.10.2003)

TITLE OF INVENTION METHODS FOR TREATING AND PREVENTING ISCHEMIA-REPERFUSION INJURY USING RNA INTERFERING AGENTS					
	T(S) FOR DO/EO/US LIEBERMAN, Judy and HAMAR, Péter				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. 🛚 Т	his is a FIRST submission of items concerning a submission under 35 U.S.C. 371.				
2 т	his is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.				
	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.				
4. X T	The US has been elected (Article 31).				
-5. X	A copy of the International Application as filed (35 U.S.C. 371(c)(2))				
	a. is attached hereto (required only if not communicated by the International Bureau).				
	b. $\overline{f X}$ has been communicated by the International Bureau.				
	c. is not required, as the application was filed in the United States Receiving Office (RO/US).				
6. 🗆	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).				
	a. is attached hereto.				
10	b. has been previously submitted under 35 U.S.C. 154(d)(4).				
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))				
	a. are attached hereto (required only if not communicated by the International Bureau).				
	b. have been communicated by the International Bureau.				
	c. have not been made; however, the time limit for making such amendments has NOT expired.				
	d. have not been made and will not be made.				
8. 🗔	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).				
9. 🗌	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).				
10.	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).				
Items 11 to 20 below concern document(s) or information included:					
11.	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.				
12.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.				
13. 🗓	A preliminary amendment.				
14. 🛛	An Application Data Sheet under 37 CFR 1.76.				
15.	A substitute specification.				
16. 🗆	A power of attorney and/or change of address letter.				
17. 🛚	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.				
18.	A second copy of the published International Application under 35 U.S.C. 154(d)(4).				
19.	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).				

IAP17 Rec'd PCT/PTO 28 APR 2006

ATTORNEY'S DOCKET NUMBER

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INTERNATIONAL APPLICATION NO.

U.S. APPLICATION NO_(if known, see 37 CFR 1.5)

107	57781	4	PCT/US200	4/036200	033393-05	55222	
20. Other items or information: Statement of Limited Recognition, Express Mail Certificate EV653003243US, Paper copy of Sequence Listing, Statement Accompanying Sequence Listing, Nine (9) Sheets of Formal Drawings of Figures 1-3C, Cover Page of PCT publication WO2005/042719 and Return Postcard.							
The following	g fees have been sub	mitted			CALCULATIONS	PTO USE ONLY	
21. X Basic national fee (37 CFR 1.492(a))					\$ 300.00		
If the written opinion p	on fee (37 CFR 1.492 prepared by ISA/US on dicates all claims sat	\$ 200.00					
If the written opinion of IPEA/US indictions of IPEA/US indictions of IPEA/US international International Search F	cates all claims satisfy .445(a)(2)) has been Searching Authority Report prepared by an nmunicated to the US	\$ 100.00					
TOT	AL OF 21, 22 and 23	600.00					
Additional fee for sequence list electronic me	specification and drawing in compliance with dium) (37 CFR 1.492) for each additional						
			ditional 50 or fraction to a whole number)	RATE			
66 - 100 = -34 /50 =				x \$250	\$ 0.00		
Surcharge of \$130.00 after the date of comm		\$ 0.00					
CLAIMS	NUMBER FILE	D	NUMBER EXTRA	RATE	\$	_	
Total claims	18	- 20 =	0	x \$ 50	\$ 0.00		
Independent claims	3	- 3 =	0	× \$200	\$ 0.00		
MULTIPLE DEPEND	ENT CLAIM(S) (if app	\$ 0.00					
		\$ 600.00					
Applicant claims	small entity status. Se	300.00					
		\$ 300.00					
Processing fee of \$13 claimed priority date (\$ 0.00					
		\$ 300.00					
Fee for recording the by an appropriate cov		\$ 0.00					
		\$	300.00				
					Amount to be refunded:	\$	
					Amount to be charged	\$	

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	10/577814						
a. A check in the amount of \$ to cover the ab	ove fees is enclosed.						
b. Please charge my Deposit Account No. 50-0850 in the amount of A duplicate copy of this sheet is enclosed.	\$ 300.00 to cover the above fees.						
The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No A duplicate copy of this sheet is enclosed.							
Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.							
SEND ALL CORRESPONDENCE TO: David S. Resnick Nixon Peabody LLP 100 Summer Street Boston, MA 02110 US	SIGNATURE David S. Resnick/Leena H. Karttunen NAME 34,235/L0207 REGISTRATION NUMBER						

IAP17 Rec'd PCT/PTO 28 APR 2006 BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATES PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Leena H. Karttunen is hereby given limited recognition under 37 CFR §11.9(b) as an employee of Nixon Peabody LLP, to prepare and prosecute patent applications wherein the patent applicant is the client of Nixon Peabody LLP and an attorney or agent of record in the applications is a registered practitioner who is a member of Nixon Peabody LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Leena H. Karttunen ceases to lawfully reside in the United States, (ii) Leena H. Karttunen's employment with Nixon Peabody LLP ceases or is terminated, or (iii) Leena H. Karttunen ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Limited Recognition No. <u>L0207</u> Expires: February 11, 2007

Harry I. Moatz

Director of Enrollment and Discipline

IAP17 Rec'd PCT/PTO 28 APR 2006

Practitioner's Docket No. 033393-055222

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lieberman, et al.

Application No.: PCT/US2004/036200 Group No.: Not yet assigned International Filing Date: 01 November 2004 Examiner: Not yet assigned

Earliest Priority Date: 30 October 2003

For: METHODS FOR TREATING AND PREVENTING ISCHEMIA-REPERFUSION

INJURY USING RNA INTERFERING AGENTS.

MAIL STOP PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

EXPRESS MAIL CERTIFICATE

"Express Mail" label number: EV653003243US

Date of Deposit: April 28, 2006

I hereby state that the following attached papers and fees:

- 1. Express Mail Certificate EV653003243US (1pg);
- 2. Statement of Limited Recognition (1pg.);
- 3. Transmittal Letter under 35 U.S.C. 371 page 3 in duplicate (4pp);
- 4. Preliminary Amendment (5pp);
- Application Data Sheet (3pp);
- 6. Formal Drawings of Figures 1-3C (9pp);
- 7. Paper copy and CRF copy of Sequence Listing (8pp and 1 disk);
- 8. Statement Accompanying Sequence Listing (1pg); and
- 9. Return Receipt Postcard.

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. section 1.10, on the date indicated above and is addressed to MAIL STOP PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Rebecca J. Goodwin

Signature of person mailing paper or fee